Back to top

Should You Buy Zoetis (ZTS) Ahead of Earnings?

Read MoreHide Full Article

Investors are always looking for stocks that are poised to beat at earnings season and Zoetis Inc. (ZTS - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Zoetis is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ZTS in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at 78 cents per share for ZTS, compared to a broader Zacks Consensus Estimate of 77 cents per share. This suggests that analysts have very recently bumped up their estimates for ZTS, giving the stock a Zacks Earnings ESP of +0.43% heading into earnings season.

Zoetis Inc. Price and EPS Surprise

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that ZTS has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Zoetis, and that a beat might be in the cards for the upcoming report.

3 Medical Stocks to Buy Now

The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.

So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.

See them today for free >>
 




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Zoetis Inc. (ZTS) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in